NEW YORK, Feb. 22 - Start-up systems-biology company Beyond Genomics on Friday said that Micromass UK Limited, a wholly-owned subsidiary of Waters, will supply its leading mass spectrometry technologies in its own systems biology drug-discovery platform.

Terms of the deal call for Waters to make an equity investment in Beyond Genomics in exchange for provisions that Beyond Genomics will buy Micromass products. The agreement also says that Micromass will have the option to license certain IP from Beyond Genomics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.